Gerostate Alpha, founded with the mission to treat aging and age-related diseases, is a pioneering pharmaceutical company incubated at the Buck Institute for Research on Aging. The company's vision is to develop breakthrough pharmaceuticals that mitigate and reduce the effects of aging through proprietary innovations. Gerostate Alpha focuses on leveraging over thirty years of research in the biology of aging to create effective treatments that challenge the inevitability of aging.
Notable affiliated individuals include researchers and scientists from the Buck Institute for Research on Aging, a leading institution in the field. Gerostate Alpha has achieved significant milestones in developing its pharmaceutical pipeline, contributing to the growing body of knowledge on aging and age-related diseases. The company's impact lies in its potential to revolutionize how society approaches aging, offering hope for extended healthspan and improved quality of life for the aging population.
